EPISODE · Jun 21, 2024 · 13 MIN
Trends in CAR T-cell Therapy
from EHA Unplugged · host European Hematology Association
Join us for a captivating interview with our guest Professor Carl June, Director of the Centre for Cellular Immunotherapies at the University of Pennsylvania, USA, as he discusses the current directions in CAR T-cell therapy. Together with our host Dr. Sarah de Vlieger, they examine the latest results on both pediatric and adult patients with over ten years of follow up. They cover ongoing trials aimed at drastically reducing the vein-to-vein time for autologous CAR T-cells, as well as trends toward academic manufacturing and the full automation of production processes. Finally, Prof. June provides insight into USA FDA’s warning about secondary malignancies in CAR T-cell-treated patients issued in November 2023. Host: Sarah de Vlieger, EHA Head of EducationGuest: Prof Carl JuneThis is the first of a series of podcasts recorded at the 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe
What this episode covers
Join us for a captivating interview with our guest Professor Carl June, Director of the Centre for Cellular Immunotherapies at the University of Pennsylvania, USA, as he discusses the current directions in CAR T-cell therapy. Together with our host Dr. Sarah de Vlieger, they examine the latest results on both pediatric and adult patients with over ten years of follow up. They cover ongoing trials aimed at drastically reducing the vein-to-vein time for autologous CAR T-cells, as well as trends toward academic manufacturing and the full automation of production processes. Finally, Prof. June provides insight into USA FDA’s warning about secondary malignancies in CAR T-cell-treated patients issued in November 2023. Host: Sarah de Vlieger, EHA Head of EducationGuest: Prof Carl JuneThis is the first of a series of podcasts recorded at the 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!Learn MoreInterested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe
NOW PLAYING
Trends in CAR T-cell Therapy
No transcript for this episode yet
Similar Episodes
Jun 24, 2026 ·20m
Jun 23, 2026 ·28m
Jun 23, 2026 ·10m
Jun 22, 2026 ·20m
Jun 19, 2026 ·70m